ABSTRACT CITATION ID: NOAE064.561
NFS-03. MEDULLOBLASTOMA IN CHILDREN WITH FANCONI ANEMIA: ASSOCIATION WITH FA-D1/FA-N, SHH TYPE AND POOR SURVIVAL INDEPENDENT OF TREATMENT STRATEGIES
Marthe Sonksen1, Denise Obrecht-Sturm1, Pablo Hernáiz Driever2,
Axel Kordes3, Norbert Graf4, Udo Konny5, Christian Reimann6,
Uwe Kordes5, Rudolf Schwarz5, Tobias Ober6, Felix Boschmann9,10,
Uwe Schuller11,12, Lea Altendorf11, Tobias Guschik13, Torsten Potsch13,
Martin Mynarek1, Stefan Rutkowski12; 1Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany; 3Pediatric Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 4Department of Pediatric Oncology and Hematology, University Hospital Saarland, Homburg, Germany; 5Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany; 6Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany; 7Department for Radiotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 8Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 9Institute of Medical Genetics and Human Genetics, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 10Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Berlin, Germany; 11Research Institute Children’s Cancer Center Hamburg, Hamburg, Germany; 12Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 13Institute of Neuropathology, Brain Tumor Reference Center of the German Society for Neuropathology and Neuroanatomy (DGNN), University of Bonn, Bonn, Germany

BACKGROUND: Outcome of children with medulloblastoma (MB) and Fanconi Anemia (FA), an inherited DNA repair deficiency, has not systematically been described. Treatment is complicated by high vulnerability to treatment-associated side effects, yet structured data are lacking. This study provides a comprehensive overview about clinical and molecular characteristics of pediatric FA MB patients. METHODS: Clinical data including detailed information on treatment and toxicities of six previously unreported FA MB patients were supplemented with data of 16 published cases. RESULTS: We identified 22 cases of children with FA and MB with clinical data available. Biological subgroup was SHH in all cases with data available (n=9), confirmed by methylation profiling in five patients. FA MB patients exclusively belonged to complementation groups FA-D1 (n=16) or FA-N (n=3). Patients were treated with postoperative chemotherapy only (50%) or radiotherapy (RT)±chemotherapy (27%). 23% did not receive adjuvant therapy. Excessive treatment-related toxicities were frequent. Severe hematological toxicity occurred in 91% of patients treated with alkylating chemotherapy, while non-alkylating agents and RT were less toxic. 14 patients (63.6%) developed 20 other malignancies, of which ten occurred before, five simultaneously with and five after MB diagnosis. Median overall survival (OS) was 1 year (95%CI 0.3-1.9), 1-year-progression-free-survival (PFS) was 26.3±10.1% and 1-year-OS was 42.1±11.3%. Adjuvant therapy prolonged survival (1y-OS/1y-PFS 0%/0% without adjuvant therapy vs. 53.3±12.9%/33.3±12.2% with adjuvant therapy, p=0.006/p=0.086), with no difference whether the patient had received chemotherapy only or RT±chemotherapy. CONCLUSIONS: MB in FA patients is strongly associated with SHH activation and FA-D1/FA-N. Despite the dismal prognosis, adjuvant therapy may improve survival. Non-alkylating chemotherapy and RT are feasible in selected patients with careful monitoring of toxicities and dose adjustments. Unlike in standard MB protocols, focal RT may be considered in FA MB patients. Curative therapy for FA MB-SHH remains an unmet medical need.